15.60
  Price15.56%   +2.10
(Pre-market: 16.14 +0.54 +3.46%)
May-17-22 08:30AM Veru to Present at the H.C. Wainwright Global Investment Conference on May 24th 2022GlobeNewswire Inc.
May-12-22 08:42AM The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And MoreBenzinga
07:45AM Veru Inc. (VERU) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research
May-12-22 06:30AM Veru Reports Second Quarter Fiscal 2022 Results and Progress of Sabizabulin for COVID-19 Toward a Request for Emergency Use AuthorizationGlobeNewswire Inc.
May-11-22 06:30AM FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 PatientsGlobeNewswire Inc.
May-10-22 09:05AM Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research
09:23AM The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO LeavesBenzinga
May-05-22 03:00AM Earnings Preview: Veru Inc. (VERU) Q2 Earnings Expected to DeclineZacks Investment Research
Apr-25-22 08:30AM Veru Announces Oral Late-Breaking Presentation of Phase 2 Data of Sabizabulin for the Treatment of Hospitalized Severe COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome at the 32nd European Congress of Clinical Microbiology & Infectious DiseasesGlobeNewswire Inc.
Apr-21-22 07:55AM Is Veru Stock a Buy Now?The Motley Fool
Apr-16-22 06:30AM This Hidden Stock Exploded by 190% in a Day. Is It a Buy?The Motley Fool
Apr-14-22 09:07AM Benzinga's Daily Brief On Trending Tickers For April 14, 2022: Morgan Stanley, Rite Aid, Twitter And MoreBenzinga
08:50AM Here's What Could Help Veru Inc. (VERU) Maintain Its Recent Price StrengthZacks Investment Research
Apr-13-22 05:36AM Why Veru Stock Soared TodayThe Motley Fool
Apr-12-22 04:07AM Why Veru's Shares Fell 21.8% on TuesdayThe Motley Fool
02:32AM Why Veru May Be Set To Double, Triple In Price And How To Play This Consolidation PatternBenzinga
Apr-12-22 08:33AM This value fund manager is sticking with Netflix and Facebook's parent — and has a new position in another megacap tech stockMarketWatch
06:59AM This value fund manager is sticking with Netflix and Facebook's parent — and has a new position in another megacap tech stockMarketWatch
Apr-11-22 05:48AM Why Veru Stock Skyrocketed TodayThe Motley Fool
02:34AM Nasdaq slumps 1.8%, leading stock indexes lower, as Treasury yields keep surgingMarketWatch
Apr-11-22 01:08AM Dr. Fauci warns: Don't 'pooh-pooh' COVID because of low hospitalizations, as new daily cases and deaths extend increasesMarketWatch
01:07AM Nasdaq slumps almost 2% amid broad stock-market selloff as Treasury yields keep surgingMarketWatch
Apr-11-22 12:46PM Dr. Fauci warns don't 'pooh-pooh' COVID because of low hospitalizations, as new daily cases and deaths extend increasesMarketWatch
11:58AM Nasdaq slumps almost 2% to lead stock-market selloff as Treasury yields continue to surge MarketWatch
Apr-11-22 09:52AM U.S. stocks fall as Treasury yields continue to surgeMarketWatch
09:36AM Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes PennyStocks
Apr-11-22 06:30AM Veru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming EfficacyGlobeNewswire Inc.
Mar-04-22 08:30AM Veru Announces Acceptance of Two Abstracts for Presentation at the 39th Miami Breast Cancer ConferenceGlobeNewswire Inc.
Feb-17-22 08:30AM Veru Announces the Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2022 ASCO Genitourinary Cancers SymposiumGlobeNewswire Inc.
Feb-14-22 08:30AM Veru Reports that Independent Data Monitoring Committee for the Phase 3 Sabizabulin COVID-19 Clinical Study Recommends Continuing Study as Planned GlobeNewswire Inc.
Feb-09-22 08:31AM The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick InBenzinga
07:45AM Veru Inc. (VERU) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research
Feb-09-22 06:30AM Veru Reports First Quarter Fiscal 2022 Results as US FC2 Prescription Net Revenues Climb 27%GlobeNewswire Inc.
Feb-02-22 03:01AM Earnings Preview: Veru Inc. (VERU) Q1 Earnings Expected to DeclineZacks Investment Research
Feb-01-22 08:30AM Veru Enters into Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate Enobosarm in Combination with Verzenio® in Phase 3 ENABLAR-2 TrialGlobeNewswire Inc.
Jan-31-22 08:30AM Veru Announces FDA Grant of Fast Track Designation for Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress SyndromeGlobeNewswire Inc.
Jan-26-22 08:30AM Veru to Report Fiscal 2022 First-Quarter Financial Results, Host Conference Call on February 9thGlobeNewswire Inc.
Jan-12-22 11:39AM Veru (VERU) Up on FDA's Fast Track Tag for Breast Cancer DrugZacks Investment Research
Jan-11-22 09:13AM Why Jim Cramer Likes Grab HoldingsBenzinga
Dec-13-21 08:30AM Veru Announces FDA Approval of ENTADFI, a New Treatment for Benign Prostatic HyperplasiaGlobeNewswire Inc.
Dec-08-21 08:00AM Veru Announces Presentation of Preclinical Evidence Supporting the Therapeutic Benefit of Enobosarm Alone or in Synergistic Combination with a CDK4/6 Inhibitor Against Palbociclib Resistant Metastatic Breast Cancer at the 2021 San Antonio Breast Cancer SymposiumGlobeNewswire Inc.
Dec-02-21 12:02PM Attention Biotech Investors: Mark Your Calendar For December PDUFA DatesBenzinga
10:20AM Veru Inc. (VERU) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research
Dec-02-21 06:30AM Veru Reports Record Fiscal 2021 Full-Year Financial ResultsGlobeNewswire Inc.
Nov-25-21 03:00AM Analysts Estimate Veru Inc. (VERU) to Report a Decline in Earnings: What to Look Out forZacks Investment Research
Veru Inc. operates as a urology and oncology biopharmaceutical company. The company operates through two segments, Commercial; and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. The company's urology drug candidates include Tamsulosin delayed release sachet and Tamsulosin XR capsules that are under bioequivalence study for the treatment of benign prostatic hyperplasia; and Solifenacin delayed release granules, which are under bioequivalence study for the treatment of overactive bladder. Its urology drug candidates also comprise Tadalafil-Finasteride combination capsules that are under bioequivalence study for the treatment of men with lower urinary tract symptoms and enlarged prostate; VERU-944, which is in Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and VERU-722 that is in Phase II clinical trial for the treatment of male infertility caused by testicular dysfunction. The company's oncology drug candidate is VERU-111, a novel oral alpha and beta tubulin inhibitor, which is under preclinical study for the treatment of metastatic prostate, breast, endometrial, ovarian, and other cancers. It also develops VERU-111/VERU-112, a novel oral agent targeting colchicine binding site that is under preclinical study for the treatment of gout and familial mediterranean fever. Veru Inc. serves agencies, non-government organizations, ministries of health, and other governmental agencies through distributors and retailers primarily in the United States, Brazil, Spain, France, and the United Kingdom. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is headquartered in Miami, Florida.
Cap:    |  Volume (24h):